Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cross-reactivity00:42

Cross-reactivity

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant.

International journal of molecular sciences·2026
Same author

Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.

Virology·2026
Same author

Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor.

Nature·2026
Same author

Omicron KP.3 RBD-Containing Spike mRNA Vaccine Induces Broadly Neutralizing Antibodies with Protection Against SARS-CoV-2 Omicron Infection in Mice.

Vaccines·2026
Same author

Novel FGFR Inhibitor Combined with Radiotherapy Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death Improving Anti-Tumor Activity.

Journal of medicinal chemistry·2025
Same author

MERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA.

Cells·2025

Related Experiment Video

Updated: May 8, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Receptor-binding domain as a target for developing SARS vaccines.

Xiaojie Zhu1, Qi Liu, Lanying Du

  • 1Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;

Journal of Thoracic Disease
|August 27, 2013
PubMed
Summary
This summary is machine-generated.

Developing safe and effective severe acute respiratory syndrome (SARS) vaccines is crucial. Research focuses on the SARS-CoV spike protein

Keywords:
Virusreceptor-binding domain (RBD)severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)spike proteinvaccine

More Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

Related Experiment Videos

Last Updated: May 8, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

Area of Science:

  • Virology and Immunology
  • Vaccine Development
  • Coronaviruses

Background:

  • Severe acute respiratory syndrome coronavirus (SARS-CoV) caused a pandemic with a 10% mortality rate.
  • Recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks raise concerns about SARS-CoV reemergence.
  • There is an ongoing need for effective and safe SARS vaccines.

Purpose of the Study:

  • To review advances in developing severe acute respiratory syndrome (SARS) vaccines.
  • To highlight the receptor-binding domain (RBD) of the SARS-CoV spike protein as a key vaccine target.
  • To explore the potential of using a similar RBD-based strategy for MERS-CoV vaccine development.

Main Methods:

  • Review of existing studies on SARS vaccine development.
  • Focus on the receptor-binding domain (RBD) within the S1 subunit of the SARS-CoV spike (S) protein.
  • Analysis of the critical neutralizing domain (CND) within the RBD.

Main Results:

  • The RBD of the SARS-CoV spike protein contains the critical neutralizing domain (CND).
  • The CND induces potent neutralizing antibody responses and cross-protection against different SARS-CoV strains.
  • RBD-based subunit vaccines are anticipated to be safer, avoiding Th2-type immunopathology.

Conclusions:

  • The RBD of the SARS-CoV spike protein is a promising target for developing safe and effective SARS vaccines.
  • RBD-based vaccines offer potential for cross-protection against divergent SARS-CoV strains.
  • The strategy for RBD-based SARS vaccines may be applicable to MERS-CoV vaccine development.